A systematic review of Hepatitis C virus treatment uptake among people who inject drugs in the European Region

BMC Infectious Diseases

Volumn 14, Issue , 2014, Pages

  Lazarus, Jeffrey V ^a   Sperle, Ida ^a   Maticic, Mojca ^b   Wiessing, Lucas ^c  

^a UNIVERSITY OF COPENHAGEN   (Denmark)

^b UNIVERSITY MEDICAL CENTRE LJUBLJANA   (Slovenia)

^c EUROPEAN MONITORING CENTRE FOR DRUGS AND DRUG ADDICTION   (Portugal)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIVIRUS AGENT; HEPATITIS C ANTIBODY; VIRUS RNA;

AGE; ARTICLE; DRUG USE; EUROPE; HEALTH SERVICE; HEPATITIS C; HIGH RISK POPULATION; HUMAN; MISCELLANEOUS NAMED GROUPS; PEOPLE WHO INJECT DRUGS; PREVALENCE; SEX; SYSTEMATIC REVIEW; WORLD HEALTH ORGANIZATION; COMPLICATION; PATIENT ATTITUDE; STATISTICS AND NUMERICAL DATA; SUBSTANCE ABUSE; TRANSMISSION;

ANTIVIRAL AGENTS; EUROPE; HEPATITIS C; HUMANS; PATIENT ACCEPTANCE OF HEALTH CARE; PREVALENCE; SUBSTANCE ABUSE, INTRAVENOUS;

EID: 84928526648     PISSN: None     EISSN: 14712334     Source Type: Journal    
DOI: 10.1186/1471-2334-14-S6-S16     Document Type: Article

References (59)

1. Mohd HK, Groeger J, Flaxman AD, Wiersma ST: Global epidemiology of hepatitis C virus infection: new estimates of age-specific antibody to HCV seroprevalence. Hepatology 2013, 57:1333-1342.
2. World Health Organization: Guidelines for the screening, care and treatment of persons with hepatitis C infection. Geneva, Switzerland; 2014.
3. Perz JF, Armstrong GL, Farrington LA, Hutin YJ, Bell BP: The contributions of hepatitis B virus and hepatitis C virus infections to cirrhosis and primary liver cancer worldwide. J Hepatol 2006, 45:529-538.
4. Lozano R, Naghavi M, Foreman K, Lim S, Shibuya K, Aboyans V, et al: Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet 2012, 380:2095-2128.
5. Hope VD, Eramova I, Capurro D, Donoghoe MC: Prevalence and estimation of hepatitis B and C infections in the WHO European Region: a review of data focusing on the countries outside the European Union and the European Free Trade Association. Epidemiol Infect 2014, 142:270-286.
6. Hahne SJ, Veldhuijzen IK, Wiessing L, Lim TA, Salminen M, Laar M: Infection with hepatitis B and C virus in Europe: a systematic review of prevalence and cost-effectiveness of screening. BMC Infect Dis 2013, 13:181.
7. EMCDDA: European Drug Report 2013: Trends and development. Lisbon, Portugal, EMCDDA; 2013.
8. Aspinall EJ, Corson S, Doyle JS, Grebely J, Hutchinson SJ, Dore GJ, et al: Treatment of hepatitis C virus infection among people who are actively injecting drugs: a systematic review and meta-analysis. Clin Infect Dis 2013, 57(Suppl 2):S80-S89.
9. Hellard M, Sacks-Davis R, Gold J: Hepatitis C treatment for injection drug users: a review of the available evidence. Clin Infect Dis 2009, 49:561-573.
10. Martin NK, Vickerman P, Miners A, Foster GR, Hutchinson SJ, Goldberg DJ, et al: Cost-effectiveness of hepatitis C virus antiviral treatment for injection drug user populations. Hepatology 2012, 55:49-57.
11. Bruggmann P: Accessing Hepatitis C patients who are difficult to reach: it is time to overcome barriers. J Viral Hepat 2012, 19:829-835.
12. Bruggmann P, Litwin AH: Models of care for the management of hepatitis C virus among people who inject drugs: one size does not fit all. Clin Infect Dis 2013, 57(Suppl 2):S56-S61.
13. Treloar C, Rance J, Backmund M: Understanding barriers to hepatitis C virus care and stigmatization from a social perspective. Clin Infect Dis 2013, 57(Suppl 2):S51-S55.
14. Liberati A, Altman DG, Tetzlaff J, Mulrow C, Gotzsche PC, Ioannidis JP, et al: The PRISMA statement for reporting systematic reviews and metaanalyses of studies that evaluate health care interventions: explanation and elaboration. PLoS Med 2009, 6:e1000100.
15. Wiessing L, Ferri M, Grady B, Kantzanou M, Sperle I, Cullen KJ, et al: Hepatitis C Virus Infection Epidemiology among People Who Inject Drugs in Europe: A Systematic Review of Data for Scaling Up Treatment and Prevention. PLoS One 2014, 9:e103345.
16. Ebner N, Wanner C, Winklbaur B, Matzenauer C, Jachmann CA, Thau K, et al: Retention rate and side effects in a prospective trial on hepatitis C treatment with pegylated interferon alpha-2a and ribavirin in opioiddependent patients. Addict Biol 2009, 14:227-237.
17. Moussalli J, Delaquaize H, Boubilley D, Lhomme JP, Merleau PJ, Sabot D, et al: Factors to improve the management of hepatitis C in drug users: an observational study in an addiction centre. Gastroenterol Res Pract 2010.
18. Witteck A, Schmid P, Hensel-Koch K, Thurnheer MC, Bruggmann P, Vernazza P: Management of hepatitis C virus (HCV) infection in drug substitution programs. Swiss Med Wkly 2011, 141:w13193.
19. Defossez G, Verneau A, Ingrand I, Silvain C, Ingrand P, Beauchant M: Evaluation of the French national plan to promote screening and early management of viral hepatitis C, between 1997 and 2003: a comparative cross-sectional study in Poitou-Charentes region. Eur J Gastroenterol Hepatol 2008, 20:367-372.
20. Van Veen M: Briefrapport Infectieziektebestrijding in de verslavingszorg in Nederland. 2009.
21. Wilkinson M, Crawford V, Tippet A, Jolly F, Turton J, Sims E, et al: Community-based treatment for chronic hepatitis C in drug users: High rates of compliance with therapy despite ongoing drug use. Alimentary Pharmacology and Therapeutics 2009, 29.
22. Cournot M, Glibert A, Castel F, Druart F, Imani K, Lauwers-Cances V, et al: Management of hepatitis C in active drugs users: experience of an addiction care hepatology unit. Gastroenterol Clin Biol 2004, 28:533-539.
23. Gazdag G, Horvath G, Szabo O, Ungvari GS: Barriers to antiviral treatment in hepatitis C infected intravenous drug users. Neuropsychopharmacol Hung 2010, 12:459-462.
24. Jowett SL, Agarwal K, Smith BC, Craig W, Hewett M, Bassendine DR, et al: Managing chronic hepatitis C acquired through intravenous drug use. QJM 2001, 94:153-158.
25. Kieran J, Dillon A, Farrell G, Jackson A, Norris S, Mulcahy F, et al: High uptake of hepatitis C virus treatment in HIV/hepatitis C virus co-infected patients attending an integrated HIV/hepatitis C virus clinic. Int J STD AIDS 2011, 22:571-576.
26. Cullen W, Stanley J, Langton D, Kelly Y, Bury G: Management of hepatitis C among drug users attending general practice in Ireland: baseline data from the Dublin area hepatitis C in general practice initiative. Eur J Gen Pract 2007, 13:5-12.
27. Hernandez FM, Rodriguez San Roman JL, Martin Suarez JM, Pena-Lopez MJ: [Acute hepatitis due to hepatitis C virus infection in the adult population]. Gastroenterol Hepatol 2009, 32:677-680.
28. Perez-Alvarez R, Garcia-Samaniego J, Sola R, Perez-Lopez R, Barcena R, Planas R, et al: Acute hepatitis C in Spain: a retrospective study of 131 cases. Rev Esp Enferm Dig 2012, 104:21-28.
29. Perut V, Labalette C, Sogni P, Ferrand I, Salmon-Ceron D, Vidal-Trecan G: Access to care of patients with chronic hepatitis C virus infection in a university hospital: Is opioid dependence a limiting condition? Drug Alcohol Depend 2009, 104:78-83.
30. Reiberger T, Obermeier M, Payer BA, Baumgarten A, Weitner L, Moll A, et al: Considerable under-treatment of chronic HCV infection in HIV patients despite acceptable sustained virological response rates in a real-life setting. Antivir Ther 2011, 16:815-824.
31. Backmund M, Meyer K, Von ZM, Eichenlaub D: Treatment of hepatitis C infection in injection drug users. Hepatology 2001, 34:188-193.
32. Grando-Lemaire V, Goisset P, Sorge F, Trinchet JC, Castera L, Roulot D, et al: [Hepatitis C virus screening in drug users in an addiction out-patient unit]. Gastroenterol Clin Biol 2002, 26:1091-1096.
33. Guadagnino V, Trotta MP, Montesano F, Babudieri S, Caroleo B, Armignacco O, et al: Effectiveness of a multi-disciplinary standardized management model in the treatment of chronic hepatitis C in drug addicts engaged in detoxification programmes. Addiction 2007, 102:423-431.
34. McCormick PA, Keavney M, O'Toole S, Moloney J: Methadone and HCV treatment. Ir Med J 2008, 101:316-317.
35. Schulte B, Schutt S, Brack J, Isernhagen K, Deibler P, Dilg C, et al: Successful treatment of chronic hepatitis C virus infection in severely opioiddependent patients under heroin maintenance. Drug Alcohol Depend 2010, 109:248-251.
36. Crespo J, Garcia F, Castro B, Pons F: Chronic hepatitis (HCV) among intravenous drug users (IDU); reasons for not initiating the antiviral treatment. [Spanish]. Adicciones 2001, 13.
37. Broers B, Helbling B, Francois A, Schmid P, Chuard C, Hadengue A, et al: Barriers to interferon-alpha therapy are higher in intravenous drug users than in other patients with acute hepatitis C. J Hepatol 2005, 42:323-328.
38. Jack K, Willott S, Manners J, Varnam MA, Thomson BJ: Clinical trial: a primary-care-based model for the delivery of anti-viral treatment to injecting drug users infected with hepatitis C. Aliment Pharmacol Ther 2009, 29:38-45.
39. Kristensen O, Sundoy A, Skeie K, Vederhus JK, Oye I, Opsal A, et al: [Shortterm treatment of Hepatitis C in heroin-dependent patients]. Tidsskr Nor Laegeforen 2009, 129:1639-1642.
40. Lindenburg CE, Lambers FA, Urbanus AT, Schinkel J, Jansen PL, Krol A, et al: Hepatitis C testing and treatment among active drug users in Amsterdam: results from the DUTCH-C project. Eur J Gastroenterol Hepatol 2011, 23:23-31.
41. World Health Organization: Global policy report on the prevention and control of viral hepatitis. 2013.
42. World Hepatitis Alliance: Global Community Hepatitis Policy Report. 2014.
43. EASL International Consensus Conference on Hepatitis C. Paris, 26-28, February 1999, Consensus Statement. European Association for the Study of the Liver. J Hepatol 1999, 30:956-961.
44. EASL Clinical Practice Guidelines: management of hepatitis C virus infection. J Hepatol 2011, 55:245-264.
45. EASL Clinical Practice Guidelines: management of hepatitis C virus infection. J Hepatol 2014, 60:392-420.
46. Overbeck K, Bruggmann P, Helbling B: Chronic Hepatitis C virus infection in Swiss primary care practices: low case loads-high barriers to treatment? Eur J Gen Pract 2011, 17:103-108.
47. John-Baptiste A, Krahn M, Heathcote J, Laporte A, Tomlinson G: The natural history of hepatitis C infection acquired through injection drug use: meta-analysis and meta-regression. J Hepatol 2010, 53:245-251.
48. Dore GJ, Hellard M, Matthews GV, Grebely J, Haber PS, Petoumenos K, et al: Effective treatment of injecting drug users with recently acquired hepatitis C virus infection. Gastroenterology 2010, 138:123-135.
49. Alvarez-Uria G, Day JN, Nasir AJ, Russell SK, Vilar FJ: Factors associated with treatment failure of patients with psychiatric diseases and injecting drug users in the treatment of genotype 2 or 3 hepatitis C chronic infection. Liver Int 2009, 29:1051-1055.
50. Melin P, Chousterman M, Fontanges T, Ouzan D, Rotily M, Lang JP, et al: Effectiveness of chronic hepatitis C treatment in drug users in routine clinical practice: results of a prospective cohort study. Eur J Gastroenterol Hepatol 2010, 22:1050-1057.
51. World Health Organization: Programmatic Update. Antiretroviral Treatment as Prevention (TASP) of HIV and TB. Geneva, World Health Organization; 2012.
52. Zeiler I, Langlands T, Murray JM, Ritter A: Optimal targeting of Hepatitis C virus treatment among injecting drug users to those not enrolled in methadone maintenance programs. Drug Alcohol Depend 2010, 110:228-233.
53. Vickerman P, Martin N, Hickman M: Can Hepatitis C virus treatment be used as a prevention strategy? Additional model projections for Australia and elsewhere. Drug Alcohol Depend 2011, 113:83-85.
54. Martin NK, Vickerman P, Foster GR, Hutchinson SJ, Goldberg DJ, Hickman M: Can antiviral therapy for hepatitis C reduce the prevalence of HCV among injecting drug user populations? A modeling analysis of its prevention utility. J Hepatol 2011, 54:1137-1144.
55. Robaeys G, Van VH, Mathei C, Van RM, Bruckers L, Buntinx F: Similar compliance and effect of treatment in chronic hepatitis C resulting from intravenous drug use in comparison with other infection causes. Eur J Gastroenterol Hepatol 2006, 18:159-166.
56. Lowry DJ, Ryan JD, Ullah N, Kelleher TB, Crowe J: Hepatitis C management: the challenge of dropout associated with male sex and injection drug use. Eur J Gastroenterol Hepatol 2011, 23:32-40.
57. Medrano J, Resino S, Vispo E, Madejon A, Labarga P, Tuma P, et al: Hepatitis C virus (HCV) treatment uptake and changes in the prevalence of HCV genotypes in HIV/HCV-coinfected patients. J Viral Hepat 2011, 18:325-330.
58. Dalgard O, Bjoro K, Hellum K, Myrvang B, Skaug K, Gutigard B, et al: Treatment of chronic hepatitis C in injecting drug users: 5 years' followup. Eur Addict Res 2002, 8:45-49.
59. Fried R, Monnat M, Seidenberg A, Oppliger R, Schmid P, Herold M, et al: Swiss multicenter study evaluating the efficacy, feasibility and safety of peginterferon-alfa-2a and ribavirin in patients with chronic hepatitis C in official opiate substitution programs. Digestion 78.